SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001493152-24-024126
Filing Date
2024-06-17
Accepted
2024-06-17 16:23:52
Documents
2
Period of Report
2024-06-13

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 6337
2 ex24-1.htm EX-24.1 12105
  Complete submission text file 0001493152-24-024126.txt   19951
Mailing Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734
Business Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Issuer) CIK: 0001815974 (see all company filings)

IRS No.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ANEBULO PHARMACEUTICALS, INC. 1415 RANCH ROAD 620 SOUTH, SUITE 201 LAKEWAY TX 78734
Business Address
Calloway Nathaniel (Reporting) CIK: 0001952771 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40388 | Film No.: 241048600